Detail Information of Exogenous Modulation
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0094 Transporter Info | ||||
Gene Name | SLC13A4 | ||||
Transporter Name | Na(+)/sulfate cotransporter SUT-1 | ||||
Gene ID | |||||
UniProt ID | |||||
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
---|---|---|---|---|---|
Chemical Compound |
|||||
DT Modulation1 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Valproic Acid affects the expression of SLC13A4 mRNA | [19] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
2,5,2',5'-tetrachlorobiphenyl |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
2,5,2',5'-tetrachlorobiphenyl analog results in decreased expression of SLC13A4 mRNA | [9] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
aristolochic acid I |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
aristolochic acid I results in increased expression of SLC13A4 mRNA | [12] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Benzo(a)pyrene |
4 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzo(a)pyrene affects the methylation of SLC13A4 promoter | [13] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Benzo(a)pyrene results in increased methylation of SLC13A4 5' UTR | [13] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Benzo(a)pyrene results in increased methylation of SLC13A4 exon | [13] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Benzo(a)pyrene results in increased mutagenesis of SLC13A4 gene | [14] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol S |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bisphenol S results in decreased expression of SLC13A4 mRNA | [15] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
di-n-butylphosphoric acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
di-n-butylphosphoric acid affects the expression of SLC13A4 mRNA | [16] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
dorsomorphin |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
entinostat |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
entinostat results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
ethyl-p-hydroxybenzoate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
ethyl-p-hydroxybenzoate results in increased expression of SLC13A4 mRNA | [17] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
exemestane |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
exemestane results in increased expression of SLC13A4 mRNA | [1] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Lactic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Lactic Acid results in decreased expression of SLC13A4 mRNA | [7] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
licochalcone B |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
licochalcone B results in decreased expression of SLC13A4 mRNA | [18] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
p-Chloromercuribenzoic Acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of SLC13A4 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
p-Chloromercuribenzoic Acid results in increased expression of SLC13A4 mRNA | [6] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Mycotoxins |
|||||
Aflatoxin B1 |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Aflatoxin B1 results in decreased methylation of SLC13A4 intron | [10] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Aflatoxin B1 results in increased methylation of SLC13A4 gene | [11] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Approved Drug |
|||||
Exemestane |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Exemestane increases the expression of SLC13A4 | [1] | |||
Amiodarone |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Amiodarone increases the expression of SLC13A4 | [2] | |||
Acetaminophen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Acetaminophen increases the expression of SLC13A4 | [3] | |||
Valproic Acid |
3 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valproic Acid increases the expression of SLC13A4 | [4] | |||
Drug in Phase 2 Trial |
|||||
MS-275 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
MS-275 increases the expression of SLC13A4 | [4] | |||
Investigative Drug |
|||||
Phenylmercuric Acetate |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Phenylmercuric Acetate increases the expression of SLC13A4 | [6] | |||
Milchsaure |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Milchsaure inhibits the expression of SLC13A4 | [7] | |||
Health and Environmental Toxicant |
|||||
tris(1,3-dichloro-2-propyl)phosphate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC13A4 | [5] | |||
Diethylhexyl Phthalate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Diethylhexyl Phthalate increases the expression of SLC13A4 | [8] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.